Onconetix Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Karina Fedasz
Chief executive officer
US$353.1k
Total compensation
| CEO salary percentage | 55.83% |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 3.3yrs |
| Board average tenure | 1.3yrs |
Recent management updates
Recent updates
Here's Why We're Not Too Worried About Blue Water Vaccines' (NASDAQ:BWV) Cash Burn Situation
Jan 24
Blue Water plans to evaluate BWV-201 vaccine for pneumococcal pneumonia
Oct 11Blue Water Vaccines stock jumps ~22% premarket on plans to develop monkeypox shot
Aug 17Blue Water Vaccines in pact to study Alzheimer’s vaccine
Jul 20Blue Water Vaccines: Estimates And Expectations
May 17CEO
Karina Fedasz (51 yo)
Ms. Karina M. Fedasz has been an Interim Chief Executive Officer of Onconetix, Inc. since April 2, 2025 and serves as its Interim Chief Financial Officer since June 10, 2024. She served as Chief Financial...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO & Interim CFO | less than a year | US$353.05k | no data | |
| Global Head of Biologics Operations | 3.9yrs | no data | no data | |
| Head of Technology Strategy | 4.7yrs | US$126.48k | no data | |
| Head of Business Development | 3.9yrs | no data | no data | |
| Head of Science & Discovery | 2.7yrs | no data | no data | |
| Chief Medical Officer | 2.1yrs | no data | no data |
Experienced Management: ONCO's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.3yrs | US$62.47k | 0.023% $ 240.5 | |
| Chairman | less than a year | no data | 0.012% $ 123.9 | |
| Independent Director | 1.3yrs | US$56.68k | 0.023% $ 246.2 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.8yrs | US$93.65k | 0.027% $ 280.6 | |
| Independent Non-Executive Director | 2.3yrs | US$83.65k | 0.024% $ 252.0 |
Experienced Board: ONCO's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/27 04:43 |
| End of Day Share Price | 2025/05/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Onconetix, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vernon Bernardino | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |